Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
12/21/2006 | US20060286171 Bone morphogenetic protein formulations |
12/21/2006 | US20060286170 Method and composition for treating cancer using cellular organelle crystallizing agents |
12/21/2006 | US20060286157 Protein mixtures for wound healing |
12/21/2006 | US20060286155 Microbiocide, pain relieving agent, antiseptic, analgesic, local anaesthetic, or kallikrein inhibitor in a matrix of a N-(2-hydroxypropyl)methacrylamide polymer crosslinked with a kallikrein-cleavable -Phe-Arg-Ser-Ser-Arg-Gln- or -Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Gln- oligopeptide sequence |
12/21/2006 | US20060286148 Method of forming implants |
12/21/2006 | US20060286146 Hemostatic compositons and methods |
12/21/2006 | US20060286140 Implants with attached silylated therapeutic agents |
12/21/2006 | US20060286129 Oral GLP-1 formulations |
12/21/2006 | US20060286125 Immunomodulation; Yatapoxvirus polypeptide; multiple sclerosis, psoriasis, atopic dermatitis, type 1 insulin-dependent diabetes mellitus, dermatitis, Sjoigren's syndrome, encephalitis, Reiter's syndrome, psoriatic arthritis, progressive systemic sclerosis, primary biliary cirrhosis |
12/21/2006 | US20060286119 Compositions and methods for treatment of chronic and infectious diseases |
12/21/2006 | US20060286117 Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury |
12/21/2006 | US20060286115 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule |
12/21/2006 | US20060286111 Tumor necrosis factor related ligand |
12/21/2006 | US20060286110 Bax-responsive genes for drug target identification in yeast and fungi |
12/21/2006 | US20060286105 Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
12/21/2006 | US20060286102 Cell surface receptor isoforms and methods of identifying and using the same |
12/21/2006 | US20060286093 secreted tumor necrosis factor receptor polypeptides; modulates B cell activation; inhibiting ztnf4 activity |
12/21/2006 | US20060286091 RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF |
12/21/2006 | US20060286088 Administration of enoxaparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction |
12/21/2006 | US20060286087 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
12/21/2006 | US20060286086 Lysozyme-based food stuff |
12/21/2006 | US20060286085 Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
12/21/2006 | US20060286084 Agent for promoting osteogenesis and/or inhibiting bone resorption |
12/21/2006 | US20060286083 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
12/21/2006 | US20060286077 Perivascular mesenchymal precursor cell induced blood vessel formation |
12/21/2006 | US20060286075 Method and compositions for treating hepatocellular cancer |
12/21/2006 | US20060286073 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
12/21/2006 | US20060286072 A replication-defective adenoviral or adeno-associated viral vector; gene therapy for congestive heart failure; antiischemic agents |
12/21/2006 | US20060286070 for extending clinical utility of interferon (IFN) alpha in treatment of a variety of viral and proliferative disorders; increase efficacy of IFN- alpha and reduce IFN- alpha treatment-related side effects |
12/21/2006 | US20060286069 G-CSF Conjugates |
12/21/2006 | US20060286068 Polypeptides exhibiting granulocyte colony-stimulating factor (G-CSF) activity; conjugates between the polypeptides and a non-polypeptide moiety (PEG); for treatment of neutropenia or leukopenia; low in vitro bioactivity, long in vivo half-life, reduced receptor-mediated clearance |
12/21/2006 | US20060286066 Pegylated immunoglobulin variable region polypeptides |
12/21/2006 | US20060286065 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro |
12/21/2006 | US20060286063 Glycoprotein IIb/IIa (GPIIb/IIIa) inhibitor such as xemilofiban and rapamycin attached to a polymer such as a polyamideester copolymer of leucine, lysine, sebacic acid and hexanediol |
12/21/2006 | US20060286041 Mrp iv inhibitors for the treatment of respiratory diseases |
12/21/2006 | US20060286039 Novel treatment for pathological aggression |
12/21/2006 | US20060286038 Pulmonary surfactant formulations |
12/21/2006 | US20060286035 Methods and compositions for modulating the interaction between adiponectin and its receptor |
12/21/2006 | US20060286033 Targeting pulmonary epithelium using ADRP |
12/21/2006 | US20060286031 Modulators of tissue regeneration |
12/21/2006 | DE102005027665A1 Pharmazeutischer Wirkstoff zur Überwindung der Blut-Hirn-Schranke in Verbindung mit einem aus biogenen Giften gewonnenen Wirkstoff gegen Hirntumore A pharmaceutical agent to cross the blood-brain barrier in connection with a drug derived from biogenic poisons against brain tumors |
12/21/2006 | DE102005027556A1 New Raf kinase inhibitor peptide useful in the preparation of medicament for the treatment of tumor |
12/21/2006 | DE10061110B4 Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms Expression of keratin genes 8 and 18 for the treatment of tumors, especially of breast cancer |
12/21/2006 | CA2612794A1 Transglutaminase mediated conjugation of growth hormone |
12/21/2006 | CA2612282A1 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
12/21/2006 | CA2612151A1 Agents and methods based on the use of the eda domain of fibronectin |
12/21/2006 | CA2612063A1 Oxyntomodulin analogues and their effects on feeding behaviour |
12/21/2006 | CA2611839A1 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
12/21/2006 | CA2611796A1 Improved antimicrobial peroxidase compositions |
12/21/2006 | CA2611715A1 Methods and systems for neural maintenance and regeneration |
12/21/2006 | CA2611256A1 Modulation of peripheral clocks in adipose tissue |
12/21/2006 | CA2611054A1 Novel a.beta.-binding protein and its peptide derivatives and uses thereof |
12/21/2006 | CA2610159A1 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals |
12/21/2006 | CA2606351A1 Adamts13-comprising compositions having thrombolytic activity |
12/21/2006 | CA2597317A1 Uses of recombinant super-compound interferons |
12/21/2006 | CA2596412A1 Anti-connexin compounds and uses thereof |
12/21/2006 | CA2574848A1 Antagonizing interleukin-21 receptor activity |
12/20/2006 | EP1734133A2 Heparanase specific molecular probes and their use in research and medical applications |
12/20/2006 | EP1734131A1 A process of manufacturing a lectin preparation, the lectin preparation and methods of administration of the preparation to mammals |
12/20/2006 | EP1734122A2 APO-2 ligand |
12/20/2006 | EP1734121A2 Genetically engineered human-derived Kunitz domains that inhibit human neutrophil elastase |
12/20/2006 | EP1734119A2 CD16-II variants |
12/20/2006 | EP1734118A1 Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening |
12/20/2006 | EP1734116A2 Thrombin derivatives and medicinal composition containing the same |
12/20/2006 | EP1734053A2 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
12/20/2006 | EP1734052A1 Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders |
12/20/2006 | EP1734051A2 Composition and methods for the diagnosis of tumours |
12/20/2006 | EP1734049A1 Tumour-associated peptides that bind to MHC-molecules |
12/20/2006 | EP1734048A1 Tumor-associated peptides that bind to MHC-molecules |
12/20/2006 | EP1733743A1 Preventives/remedies for cancer |
12/20/2006 | EP1733739A1 sFRP EXPRESSION POTENTIATING AGENT |
12/20/2006 | EP1733738A1 Method of preventing ultraviolet ray-induced apoptosis |
12/20/2006 | EP1733736A2 Method of producing recombinant antibodies against tumours |
12/20/2006 | EP1733734A2 Placental alkaline phosphatase to control diabetes |
12/20/2006 | EP1733733A1 Regulator for adiponectin receptor expression |
12/20/2006 | EP1733619A1 Use of an active agent for denaturation of the keratin of animal hairs |
12/20/2006 | EP1733618A1 Use of an active agent for the inhibition of mould spores |
12/20/2006 | EP1733237A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
12/20/2006 | EP1733231A2 Peptides and peptidomimetics binding to cd23 |
12/20/2006 | EP1733034A2 Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
12/20/2006 | EP1732942A2 Synthetic chemokines, methods of manufacture, and uses |
12/20/2006 | EP1732939A2 Nucleic acid based assays for identification of fc receptor polymorphisms |
12/20/2006 | EP1732609A2 Conjugates of hydroxyalkyl starch and a protein |
12/20/2006 | EP1732608A2 Folate conjugates and complexes |
12/20/2006 | EP1732596A2 Therapeutic use of rm1 antigen |
12/20/2006 | EP1732594A2 Method for the delivery of sustained release agents |
12/20/2006 | EP1732593A1 Use of epi-hne 1-4 |
12/20/2006 | EP1732592A1 Use of neuropeptides for ligament healing |
12/20/2006 | EP1732591A2 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
12/20/2006 | EP1732590A2 New pharmaceutical composition based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
12/20/2006 | EP1732589A2 Bmp-3 propeptides and related methods |
12/20/2006 | EP1732588A2 Modulation of nkg2d |
12/20/2006 | EP1732587A2 Methods of protein fractionation using high performance tangential flow filtration |
12/20/2006 | EP1732586A1 Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion |
12/20/2006 | EP1732585A1 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins |
12/20/2006 | EP1732584A2 Multi-component biological transport systems |
12/20/2006 | EP1732583A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
12/20/2006 | EP1732582A2 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
12/20/2006 | EP1732581A2 Polypeptide transduction and fusogenic peptides |
12/20/2006 | EP1732580A2 Epha2 vaccines |